drugset / Trial / NCT00857311
MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
RandomizedParallel-groupDouble-blindTreatment
Summary
A Study to assess the general safety and tolerability of the administration of a 3-dose prime/boost regimen of the MRKAd5 HIV-1 gag vaccine (V520) in subjects with chronic hepatitis C virus infection.
Timeline
- Start
- 2004-05
- Primary completion
- 2006-01
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MRKAd5 HIV-1 gag vaccine | Vaccine | 1e+09 unknown | Intramuscular |
| Subject | MRKAd5 HIV-1 gag vaccine | Vaccine | 1e+10 unknown | Intramuscular |
| Comparator | Tetanus and Diptheria Toxoids Adsorbed | Unknown | 0.5 ml | Intramuscular |